Medications
Resources
Basic InformationMore InformationLatest News
Health Tip: Packing Prescriptions for TravelDrug Errors Peak in July When New Docs StartFDA Warns Consumers Against Swallowing Topical BenadrylStudy Shows Some Anti-Seizure Meds Raise Suicide RiskPrescriptions Translated to Spanish Could Be Hazardous to HealthTougher-to-Abuse Form of OxyContin ApprovedVaccines-By-Patch Good News for Needle-PhobicRifaximin Maintains Remission in Patients With Liver DiseaseMenstrual Cramps May Be Helped by New DrugNew Inhaled Insulin Shows Promise for DiabetesPlavix Can Help Cut Death Risk in Certain Heart PatientsFDA Asks Docs to Suspend Using Glaxo Rotavirus VaccineFDA Says High-Dose Simvastatin Ups Myopathy RiskHigh-Dose Zocor Boosts Muscle Injury Risk: FDAAvandia Researchers' Financial Ties QuestionedCarbaglu Approved for Rare Genetic DisorderACC: New Dual-Acting Drug Lowers Blood PressureNewer Blood Thinner Beats Plavix for Bypass PatientsArthritis Drug May Fight Diabetes, Too2 Drugs Fail to Prevent Diabetes in the OverweightFDA Adds Boxed Warning to Clopidogrel LabelThiazolidinediones Not Linked to Diabetic Macular EdemaYoung Kids to Benefit From Broader Pneumococcal VaccineBleeding Alert Sounded for Stroke DrugsLink Between Diabetes and Neuroleptic Drugs OutlinedResistance Likely to Develop With New Hepatitis C DrugsLasofoxifene Examined in Postmenopausal WomenSuccessor to Combination Pneumococcal Vaccine ApprovedMenveo Vaccine Approved for Bacterial MeningitisFDA: No Decision on Whether to Pull Diabetes Drug Avandia Off the MarketRituxan Approved for Chronic Lymphocytic LeukemiaNew Technology Could Widen Reach of VaccinesFDA Issues Warning on Key Asthma DrugsFDA Issues Maalox Total Relief WarningIbuprofen May Help Stave Off Parkinson'sFDA Tightens Controls on Anemia DrugsAdded Drug Aids MS Treatment'Fishy Smell' May Keep Patients From Diabetes DrugBotox May Prevent Some MigrainesAnother Study Refutes Vaccination-Autism LinkCrestor Approval ExpandedParoxetine May Compromise the Efficacy of TamoxifenNeedle Length May Affect Vaccination Results in ObeseDrug May Ease Cognitive Effects of Huntington'sGlaucoma Drugs May Play Role in Longer LifeH1N1 Vaccination Still Highly RecommendedThe Lancet Retracts Study Linking MMR Vaccine, AutismXiaflex Approved for Rare Hand ConditionAntidepressants After Stroke May Boost Mental AbilityFDA Revises Label for the HIV Drug Didanosine
Questions and AnswersLinksBook Reviews
Related Topics

Anxiety Disorders
Depression: Major Depression & Unipolar Varieties
Medical Disorders
Mental Disorders
Mental Health Professions

Menstrual Cramps May Be Helped by New Drug

HealthDay News
by -- Robert Preidt
Updated: Mar 24th 2010

new article illustration

TUESDAY, March 23 (HealthDay News) -- A new drug shows promise in treating severe menstrual cramps, researchers say.

The condition, called dysmenorrhea, affects 45 percent to 90 percent of women of child-bearing age and is the leading cause of school and job absenteeism among women in their teens and 20s, according to a news release from the American Chemical Society. Existing treatments, such as pain relievers, anti-inflammatory drugs and oral contraceptives, are ineffective in nearly one-third of women with moderate to severe dysmenorrhea, the news release noted.

Menstrual cramps are caused by contractions of the uterus. In dysmenorrhea, the uterus contracts with increased frequency.

The British pharmaceutical company Vantia Ltd. has developed an investigational pill, called VA111913, that's designed to block the hormone vasopressin, which plays a role in regulating contraction of the uterus.

Last year, a stage 1 clinical trial showed that VA111913 was safe. The drug is currently in Phase 2 clinical trials to evaluate how well it works to control pain in women with dysmenorrhea. The results of the studies, which are being conducted by Vantia, are expected later this year.

"We hope that the drug will provide a more effective treatment option for millions of women worldwide with this painful condition," Vantia's Andrzej R. Batt, said in the news release. "Dysmenorrhea not only diminishes the quality of life for millions of women, but also has a hidden, society-wide economic cost that involves an enormous number of days lost from work and school."

Details about the drug were to be presented Tuesday at the national meeting of the American Chemical Society in San Francisco.

More information

The University of Wisconsin has more about painful menstrual periods.

Home Administration & Departments Privacy Policy
Board of Trustees Employment Opportunities
Copyright © CenterSite, LLC, 1995-2005